ES008, a potential best-in-class asset, targets myloid immunesuppressive cells, promoting pro-inflammatory cytokine production and mediate M2 to M1 macrophage switch.
MOA:
Differentially expressed on myeloid lineage cells; Promote differentiation of M2-like macrophages; Distinct additional functional effects for potential differentiation of assets.
